Here’s why it’s important to look for HDV coinfection in patients with HBV.
The role of host factors in the monitoring and treatment of chronic hepatitis B is an area largely unexplored by the guidelines. Here’s my approach to assessing patients for treatment candidacy in the setting of other host factors.
This concise MedicalMinute presentation reviews the EASL recommendations for the individualizing treatment of HBV infection in persons at risk of renal or bone disease and pregnant women.
Hear expert insights on when to treat HBV: which factors to consider and how often to monitor them.
In episode 4 of this ongoing series, listen to a conversation between Geoffrey M. Dusheiko, MD, FCP(SA), FRCP, and his patient Mark, who presented with hepatitis B after receiving immunomodulatory treatment for rheumatoid arthritis.
Review key data and EASL guideline recommendations on individualizing treatment for patients with HBV, including patients with renal or bone disease and pregnant women.